1. Home
  2. TELA vs BTAI Comparison

TELA vs BTAI Comparison

Compare TELA & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TELA Bio Inc.

TELA

TELA Bio Inc.

HOLD

Current Price

$0.73

Market Cap

41.3M

Sector

Health Care

ML Signal

HOLD

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$1.37

Market Cap

35.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TELA
BTAI
Founded
2012
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.3M
35.8M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
TELA
BTAI
Price
$0.73
$1.37
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$2.00
$23.00
AVG Volume (30 Days)
90.2K
598.3K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
37.59
75.63
EPS
N/A
N/A
Revenue
$80,275,000.00
N/A
Revenue This Year
$10.23
$197.82
Revenue Next Year
$14.26
$910.15
P/E Ratio
N/A
N/A
Revenue Growth
15.84
N/A
52 Week Low
$0.50
$1.01
52 Week High
$2.19
$8.08

Technical Indicators

Market Signals
Indicator
TELA
BTAI
Relative Strength Index (RSI) 40.32 62.37
Support Level $0.67 $1.36
Resistance Level $0.75 $1.39
Average True Range (ATR) 0.09 0.08
MACD -0.01 0.02
Stochastic Oscillator 19.29 78.04

Price Performance

Historical Comparison
TELA
BTAI

About TELA TELA Bio Inc.

TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: